Eribulin

Generic Name: Eribulin

Brand Names: Halaven, Eribulin Baxter, Mevlyq

Drug Type: Small Molecule

Chemical Formula: C_₄₀H_₅₉NO_₁₁

CAS Number: 253128-41-5

Unique Ingredient Identifier: LR24G6354G

Background: Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .

Indication: For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.

Associated Conditions: Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma

Clinical Trials

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Phase 1

Completed

Conditions: Recurrent Ovarian Cancer
HER2-Negative Metastatic Breast Cancer

Interventions: Drug: Durvalumab
Drug: Eribulin

First Posted Date: 2018-02-13

Last Posted Date: 2020-08-05

Lead Sponsor: Amy Tiersten

Target Recruit Count: 9

Registration Number: NCT03430518

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Eribulin Mesylate

First Posted Date: 2018-01-29

Last Posted Date: 2018-02-27

Lead Sponsor: Tan Tock Seng Hospital

Target Recruit Count: 14

Registration Number: NCT03412955

Locations: 🇸🇬
Tan Tock Seng Hospital, Singapore, Singapore
🇨🇳
Chang-Gung Memorial Hospital, Taoyuan city, Taiwan

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Terminated

Conditions: Breast Cancer
Breast Neoplasms

Interventions: Drug: Taxane
Drug: Eribulin
Drug: Vinorelbine
Drug: Ixabepilone
Drug: Chemotherapy

First Posted Date: 2018-01-08

Last Posted Date: 2024-06-25

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 5

Registration Number: NCT03393741

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Liposarcoma
Malignant Abdominal Neoplasm
Malignant Retroperitoneal Neoplasm
Malignant Scrotal Neoplasm
Malignant Solid Neoplasm
Malignant Spermatic Cord Neoplasm

Interventions: Drug: Eribulin Mesylate
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2017-12-04

Last Posted Date: 2025-04-02

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 15

Registration Number: NCT03361436

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Phase 2

Active, not recruiting

Conditions: Angiosarcoma
Epithelioid Hemangioendothelioma

Interventions: Drug: Eribulin

First Posted Date: 2017-11-06

Last Posted Date: 2024-11-08

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 13

Registration Number: NCT03331250

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Phase 3

Conditions: Breast Cancer

Interventions: Drug: Pertuzumab
Drug: Trastuzumab
Drug: Docetaxel
Drug: Eribulin
Drug: Paclitaxel

First Posted Date: 2017-08-29

Last Posted Date: 2017-09-21

Lead Sponsor: Japan Breast Cancer Research Group

Target Recruit Count: 480

Registration Number: NCT03264547

Locations: 🇯🇵
National Hospital Organization Osaka National Hospital, Ōsaka, Osaka, Japan
🇯🇵
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Refractory or Recurrent Solid Tumors
Non-Rhabdomyosarcoma Soft Tissue Sarcoma
Rhabdomyosarcoma
Ewing Sarcoma

Interventions: Drug: Eribulin mesilate
Drug: Irinotecan hydrochloride

First Posted Date: 2017-08-10

Last Posted Date: 2022-06-28

Lead Sponsor: Eisai Inc.

Target Recruit Count: 40

Registration Number: NCT03245450

Locations: 🇩🇪
Eisai Trial Site 6, Essen, Germany
🇩🇪
Eisai Trial Site 1, Aachen, Nordrhein-Westfalen, Germany
🇮🇹
Ospedale Infantile Regina Margherita, Torino, Piemonte, Italy

and more 36 locations

Halaven Patient Registry (Metastatic Breast Cancer, MBC)

Conditions: Advanced Breast Cancer
Metastatic Breast Cancer

First Posted Date: 2017-08-10

Last Posted Date: 2017-08-16

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 500

Registration Number: NCT03245112

Locations: 🇨🇳
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Phase 2

Active, not recruiting

Conditions: Locally Advanced Ureter Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Recurrent Ureter Urothelial Carcinoma
Stage III Bladder Cancer AJCC v8
Stage III Ureter Cancer AJCC v8
Locally Advanced Urethral Urothelial Carcinoma
Recurrent Renal Pelvis Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Recurrent Bladder Urothelial Carcinoma

Interventions: Drug: Atezolizumab
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography with Contrast
Drug: Eribulin Mesylate

First Posted Date: 2017-08-03

Last Posted Date: 2025-04-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT03237780

Locations: 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States

and more 18 locations

Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Pembrolizumab
Drug: Eribulin

First Posted Date: 2017-07-19

Last Posted Date: 2025-02-19

Lead Sponsor: MedSIR

Target Recruit Count: 44

Registration Number: NCT03222856

Locations: 🇪🇸
Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸
Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy